Earnings Feed
Start Free
Home/Filings/4/0000899243-20-018150
4//SEC Filing

Flagship Ventures Fund IV General Partner LLC 4

Accession 0000899243-20-018150

CIK 0001694665other
View on SEC.govCompany Profile

Filed

Jun 30, 8:00 PM ET

Accepted

Jul 1, 5:24 PM ET

Size

28.4 KB

Accession

0000899243-20-018150

Insider Transaction Report

Form 4
Period: 2020-06-29
Evelo Biosciences, Inc.EVLO
Flagship Ventures Fund IV General Partner LLC
10% Owner
Transactions
  • Purchase

    Common Stock

    2020-06-29$3.75/sh+1,666,667$6,250,001→ 4,079,032 total(indirect: See Footnote)
  • Purchase

    Common Stock

    2020-06-29$3.75/sh+1,333,333$4,999,999→ 3,170,169 total(indirect: See Footnote)
  • Purchase

    Common Stock

    2020-06-29$3.75/sh+333,333$1,249,999→ 782,244 total(indirect: See Footnote)
Holdings

  • Common Stock

    (indirect: See Footnote)
    2,645,637

  • Common Stock

    (indirect: See Footnote)
    1,609,871

  • Common Stock

    (indirect: See Footnote)
    684,372

  • Common Stock

    (indirect: See Footnote)
    4,201,284

  • Common Stock

    (indirect: See Footnote)
    3,598,177

  • Common Stock

    (indirect: See Footnote)
    795,950
Flagship Ventures Fund IV-Rx, L.P.
10% Owner
Transactions
  • Purchase

    Common Stock

    2020-06-29$3.75/sh+333,333$1,249,999→ 782,244 total(indirect: See Footnote)
  • Purchase

    Common Stock

    2020-06-29$3.75/sh+1,333,333$4,999,999→ 3,170,169 total(indirect: See Footnote)
  • Purchase

    Common Stock

    2020-06-29$3.75/sh+1,666,667$6,250,001→ 4,079,032 total(indirect: See Footnote)
Holdings

  • Common Stock

    (indirect: See Footnote)
    3,598,177

  • Common Stock

    (indirect: See Footnote)
    4,201,284

  • Common Stock

    (indirect: See Footnote)
    684,372

  • Common Stock

    (indirect: See Footnote)
    2,645,637

  • Common Stock

    (indirect: See Footnote)
    1,609,871

  • Common Stock

    (indirect: See Footnote)
    795,950
Flagship Ventures Opportunities Fund I, L.P.
10% Owner
Transactions
  • Purchase

    Common Stock

    2020-06-29$3.75/sh+1,666,667$6,250,001→ 4,079,032 total(indirect: See Footnote)
  • Purchase

    Common Stock

    2020-06-29$3.75/sh+1,333,333$4,999,999→ 3,170,169 total(indirect: See Footnote)
  • Purchase

    Common Stock

    2020-06-29$3.75/sh+333,333$1,249,999→ 782,244 total(indirect: See Footnote)
Holdings

  • Common Stock

    (indirect: See Footnote)
    684,372

  • Common Stock

    (indirect: See Footnote)
    4,201,284

  • Common Stock

    (indirect: See Footnote)
    1,609,871

  • Common Stock

    (indirect: See Footnote)
    795,950

  • Common Stock

    (indirect: See Footnote)
    2,645,637

  • Common Stock

    (indirect: See Footnote)
    3,598,177
Flagship Ventures Opportunities Fund I General Partner LLC
10% Owner
Transactions
  • Purchase

    Common Stock

    2020-06-29$3.75/sh+1,666,667$6,250,001→ 4,079,032 total(indirect: See Footnote)
  • Purchase

    Common Stock

    2020-06-29$3.75/sh+333,333$1,249,999→ 782,244 total(indirect: See Footnote)
  • Purchase

    Common Stock

    2020-06-29$3.75/sh+1,333,333$4,999,999→ 3,170,169 total(indirect: See Footnote)
Holdings

  • Common Stock

    (indirect: See Footnote)
    684,372

  • Common Stock

    (indirect: See Footnote)
    3,598,177

  • Common Stock

    (indirect: See Footnote)
    1,609,871

  • Common Stock

    (indirect: See Footnote)
    795,950

  • Common Stock

    (indirect: See Footnote)
    2,645,637

  • Common Stock

    (indirect: See Footnote)
    4,201,284
Flagship Ventures Fund IV, L.P.
10% Owner
Transactions
  • Purchase

    Common Stock

    2020-06-29$3.75/sh+1,333,333$4,999,999→ 3,170,169 total(indirect: See Footnote)
  • Purchase

    Common Stock

    2020-06-29$3.75/sh+333,333$1,249,999→ 782,244 total(indirect: See Footnote)
  • Purchase

    Common Stock

    2020-06-29$3.75/sh+1,666,667$6,250,001→ 4,079,032 total(indirect: See Footnote)
Holdings

  • Common Stock

    (indirect: See Footnote)
    4,201,284

  • Common Stock

    (indirect: See Footnote)
    3,598,177

  • Common Stock

    (indirect: See Footnote)
    684,372

  • Common Stock

    (indirect: See Footnote)
    795,950

  • Common Stock

    (indirect: See Footnote)
    2,645,637

  • Common Stock

    (indirect: See Footnote)
    1,609,871
AFEYAN NOUBAR
Director10% Owner
Transactions
  • Purchase

    Common Stock

    2020-06-29$3.75/sh+1,333,333$4,999,999→ 3,170,169 total(indirect: See Footnote)
  • Purchase

    Common Stock

    2020-06-29$3.75/sh+1,666,667$6,250,001→ 4,079,032 total(indirect: See Footnote)
  • Purchase

    Common Stock

    2020-06-29$3.75/sh+333,333$1,249,999→ 782,244 total(indirect: See Footnote)
Holdings

  • Common Stock

    (indirect: See Footnote)
    3,598,177

  • Common Stock

    (indirect: See Footnote)
    2,645,637

  • Common Stock

    (indirect: See Footnote)
    4,201,284

  • Common Stock

    (indirect: See Footnote)
    795,950

  • Common Stock

    (indirect: See Footnote)
    1,609,871

  • Common Stock

    (indirect: See Footnote)
    684,372
Footnotes (14)
  • [F1]On June 29, 2020, Flagship Ventures Fund IV, L.P. ("Flagship Fund IV") acquired 1,333,333 shares pursuant to an underwritten public offering of common stock by the Issuer (the "Offering").
  • [F10]Shares held by Flagship VentureLabs V LLC ("VentureLabs V"). Flagship VentureLabs V Manager LLC ("VentureLabs V Manager") serves as manager of VentureLabs V. Flagship Pioneering is the manager of VentureLabs V Manager. Dr. Afeyan serves as sole director of Flagship Pioneering. Each of the reporting persons except for VentureLabs V disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein.
  • [F11]Shares held by Flagship Ventures Fund V, L.P. ("Flagship Fund V"). Flagship Ventures Fund V General Partner LLC ("Flagship Fund V GP") is the general partner of Flagship Fund V. Dr. Afeyan serves as sole manager of Flagship Fund V. Each of the reporting persons except for Flagship Fund V disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein.
  • [F12]Shares held by Flagship V VentureLabs Rx Fund, L.P. ("VentureLabs Rx V"). Flagship Fund V GP is the general partner of VentureLabs Rx V. Dr. Afeyan serves as sole manager of Flagship Fund V GP. Each of the reporting persons except for VentureLabs Rx V disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein.
  • [F13]Shares held by Nutritional Health Side Fund, L.P. ("Nutritional Health Side Fund"). Flagship Fund V GP is the general partner of Nutritional Health Side Fund. Dr. Afeyan serves as sole manager of Flagship Fund V GP. Each of the reporting persons except for Nutritional Health Side Fund disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein.
  • [F14]Shares held by Nutritional Health Disruptive Innovation Fund, L.P. ("Nutritional Innovation Fund"). Flagship Fund V GP is the general partner of Nutritional Innovation Fund. Dr. Afeyan serves as sole manager of Flagship Fund V GP. Each of the reporting persons except for Nutritional Innovation Fund disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein.
  • [F2]Shares held by Flagship Fund IV. Flagship Ventures Fund IV General Partner LLC ("Flagship Fund IV GP") is the general partner of Flagship Fund IV. Noubar B. Afeyan, Ph.D. ("Dr. Afeyan") is the sole manager of Flagship Fund IV GP. Each of the reporting persons except for Flagship Fund IV disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein. Edwin M. Kania, Jr. is retired both from Flagship Pioneering, Inc. ("Flagship Pioneering") and as a manager of Flagship Fund IV GP.
  • [F3]On June 29, 2020, Flagship Ventures Fund IV-Rx, L.P. ("Flagship Fund IV-Rx") acquired 333,333 shares pursuant to the offering.
  • [F4]Shares held by Flagship Fund IV-Rx. Flagship Fund IV GP is the general partner of Flagship Fund IV-Rx. Dr. Afeyan is the sole manager of Flagship Fund IV GP. Each of the reporting persons except for Flagship Fund IV-Rx disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein.
  • [F5]On June 29, 2020, Nutritional Health LTP Fund, L.P. ("Nutritional LTP") acquired 1,333,333 shares pursuant to the Offering.
  • [F6]Shares held by Nutritional LTP. Nutritional Health LTP Fund General Partner LLC ("Nutritional LTP GP") is the general partner of Nutritional LTP. Dr. Afeyan is the sole member and manager of Nutritional LTP GP. Each of the reporting persons except for Nutritional LTP disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein.
  • [F7]On June 29, 2020, Flagship Ventures Opportunities Fund I, L.P. ("Flagship Opportunities I") acquired 1,666,667 shares pursuant to the Offering.
  • [F8]Shares held by Flagship Opportunities I. Flagship Ventures Opportunities Fund I General Partner LLC ("Flagship Opportunities GP") is the general partner of Flagship Opportunities I. Dr. Afeyan is the sole manager of Flagship Opportunities GP. Each of the reporting persons except for Flagship Opportunities I disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein.
  • [F9]Shares held by Flagship VentureLabs IV, LLC ("VentureLabs IV"). Flagship Fund IV is a member of VentureLabs IV and also serves as its manager. Flagship Fund IV GP is the general partner of Flagship Fund IV. Dr. Afeyan is the sole manager of Flagship Fund IV GP. Each of the reporting persons except for VentureLabs IV disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein.

Documents

1 file

Issuer

Evelo Biosciences, Inc.

CIK 0001694665

→
Entity typeother
IncorporatedDE

Related Parties

1
  • filerCIK 0001508051

Filing Metadata

Form type
4
Filed
Jun 30, 8:00 PM ET
Accepted
Jul 1, 5:24 PM ET
Size
28.4 KB
View on SEC.gov